Analysts have recently evaluated GoodRx Holdings and provided 12-month price targets. The average target is $4.16, accompanied by a high estimate of $6.00 and a low estimate of $2.75. This current ...
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the healthcare technology stocks, including GoodRx ...
GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of Ozempic (semaglutide) and Wegovy (semaglutide) pens are available to eligible ...
Key Insights Significant control over GoodRx Holdings by individual investors implies that the general public has ...
Fintel on MSN
Jefferies downgrades GoodRx Holdings (GDRX)
Fintel reports that on January 22, 2026, Jefferies downgraded their outlook for GoodRx Holdings (NasdaqGS:GDRX) from Buy to ...
GoodRx offers compelling value after a ~50% stock decline over the past 12 months, trading at just 6.1x FY25 adjusted EBITDA despite recent execution challenges. A new Novo Nordisk partnership for ...
GoodRx announced that eligible self-paying patients can now access all strengths of Ozempic and Wegovy pens for $499 per month through its platform, effective immediately. The collaboration marks the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results